Histone Deacetylase Inhibitors as Cancer Therapeutics PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Histone Deacetylase Inhibitors as Cancer Therapeutics PDF full book. Access full book title Histone Deacetylase Inhibitors as Cancer Therapeutics by Steven Grant. Download full books in PDF and EPUB format.
Author: Steven Grant
Publisher: Academic Press
ISBN: 0123943876
Category : Business & Economics
Languages : en
Pages : 290
Get Book Here
Book Description
Provides information on the exciting and fast-moving field of cancer research.
Author: Steven Grant
Publisher: Academic Press
ISBN: 0123943876
Category : Business & Economics
Languages : en
Pages : 290
Get Book Here
Book Description
Provides information on the exciting and fast-moving field of cancer research.
Author: Christiane Pienna Soares
Publisher: Frontiers Media SA
ISBN: 2889668355
Category : Science
Languages : en
Pages : 260
Get Book Here
Book Description
Author: Shabir Ahmad Ganai
Publisher: Springer Nature
ISBN: 9811581797
Category : Medical
Languages : en
Pages : 266
Get Book Here
Book Description
This book reviews the latest developments in the design, synthesis, and molecular mechanism of action of Histone Deacetylase (HDAC) inhibitors in the context of potential cancer therapy. HDAC inhibitors are emerging as promising anticancer drug molecules that promote growth arrest, differentiation and apoptosis of cancer cells with tumor selective toxicity. The book begins with an overview of various epigenetic modifying enzymes that are involved in cancer transition and progression; before exploring the potential of HDACs in cancer treatment. It provides a classification of HDAC inhibitors based on their structural attributes, and addresses HDAC-induced cytotoxicity.. Lastly, it discusses and assesses the rationale behind therapies that combine HDAC inhibitors with other anticancer agents to treat solid tumors. Given its scope, it offers a valuable resource for all researchers, clinicians, and students working in formulation, drug discovery, oncology, and personalized medicine.
Author: Pedro Castelo-Branco
Publisher: Academic Press
ISBN: 0128164220
Category : Science
Languages : en
Pages : 490
Get Book Here
Book Description
Histone Modifications in Therapy provides an in-depth analysis of the role of histone mechanisms in major diseases and the promise of targeting histone modifications for disease prevention and treatment. Here, researchers, clinicians and students will discover a thorough, evidence-based discussion of the biology of histones, the diseases engaged by aberrant histone modifications, and pathways with therapeutic potential. Expert chapter addresses the role of histone modifications across a variety of disorders, including cancer, neuropsychiatric, neurodegenerative, cardiac, metabolic, infectious, bacterial, autoimmune and inflammatory disorders, among others. In relation to these disease types, histone modifications are discussed, both as mechanisms of prevention and possible treatment. A concluding chapter brings together future perspectives for targeting histone modifications in therapy and next steps in research. Examines the use of histone modifications in disease prevention and therapy Explores the role of histone modifications in cancer, neuropsychiatric, neurodegenerative, cardiac, metabolic, infectious, bacterial, and inflammatory disease, among others Features chapters from a broad range of international authors and disease specialists
Author: Shambhunath Choudhary
Publisher:
ISBN:
Category :
Languages : en
Pages : 221
Get Book Here
Book Description
Activating mutations of ras genes are frequently found in human cancers. Since Ras proteins and their functions play an important role in tumorigenesis, it is important to develop targeted anticancer therapeutics against Ras-related human cancers. We observed that in addition to tumorigenic ability, oncogenic H-Ras possesses a novel proapoptotic ability to facilitate the induction of apoptosis by histone deacetylase inhibitors (HDACIs), such as FR901228 and trichostatin A (TSA). HDACIs make up a new class of structurally diverse anticancer agents and have been shown to exhibit antimetastatic and antiangiogenic activities toward malignantly transformed cells. We detected that expression of oncogenic H-Ras potentiated intracellular reactive oxygen species (ROS) in human and mouse cells to enhance HDACI-induced ROS, thereby contributing to the induction of selective apoptosis and caspase activation. The first part (Part I) of this dissertation focuses on the understanding of Ras proteins, their role in normal and transformed cell physiology, and current treatment options against Ras-related human cancers, as well as the role of HDACIs and ROS in anticancer therapeutics. The next three parts (Part II-IV) focus on revealing the mechanisms for the novel pro-apoptotic ability of oncogenic H-Ras that allow HDACIs to induce selective apoptosis of the oncogenic H-Ras expressing cells. Results in Part II & III verify the pro-apoptotic activity of oncogenic H-Ras in the increased susceptibility of human cancer cells to HDACIs. The caspase pathways, the B-Raf and extracellular signal regulated kinase pathway, p21[superscript Cip]1 and p27[superscript Kip]1, and core histone contents are regulated differently by FR901228 in oncogenic H-Ras-expressed cells than their counterparts in parental cells, contributing to the increased susceptibility to the induction of selective apoptosis. Results in Part IV describe the role of reactive oxygen species in the pro-apoptotic ability of oncogenic H-Ras to enhance the cell susceptibility to HDACIs. Intracellular ROS was cooperatively up-regulated by oncogenc H-Ras and HDACI treatment to induce selective apoptosis of oncogenic H-Ras-expressing cells. The last section (Part V) summarizes the findings with their importance and discusses future directions.
Author: Julia Gajer
Publisher:
ISBN:
Category :
Languages : en
Pages :
Get Book Here
Book Description
Author: Chris Rundfeldt
Publisher: IntechOpen
ISBN: 9789533072579
Category : Medical
Languages : en
Pages : 656
Get Book Here
Book Description
This book represents a case study based overview of many different aspects of drug development, ranging from target identification and characterization to chemical optimization for efficacy and safety, as well as bioproduction of natural products utilizing for example lichen. In the last section, special aspects of the formal drug development process are discussed. Since drug development is a highly complex multidisciplinary process, case studies are an excellent tool to obtain insight in this field. While each chapter gives specific insight and may be read as an independent source of information, the whole book represents a unique collection of different facets giving insight in the complexity of drug development.
Author: Henri Lichenstein
Publisher:
ISBN:
Category :
Languages : en
Pages : 26
Get Book Here
Book Description
The present invention relates generally to methods for treating cancer. In one respect, the present invention relates to a method of treating a hematological cancer (e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof a therapeutically effective amount of a histone deacetylase inhibitor, for example, a histone deacetylase (HDAC) inhibitor as described herein, for example, PXD-101. In another respect, the present invention relates to a method of treating cancer (e.g., solid tumor cancer, e.g., rectal cancer, colon cancer, ovarian cancer, hematological cancer, e.g., multiple myeloma, leukemia, lymphoma) comprising administering to a patient in need thereof, a first amount of a histone deacetylase (HDAC) inhibitor, for example, a histone deacetylase inhibitor as described herein, for example, PXD-101, and a second amount of another chemotherapeutic agent, for example, another chemotherapeutic agent selected from: an antibody against VEGF, AVASTIN.RTM. (bevacizumab), an antibody against CD20, rituximab, bortezomib, thalidomide, dexamethasone, vincristine, doxorubicin, and melphalan, wherein the first and second amounts together comprise a therapeutically effective amount.
Author: Avineesh Singh
Publisher: LAP Lambert Academic Publishing
ISBN: 9783845417752
Category :
Languages : en
Pages : 80
Get Book Here
Book Description
Leukemia is a type of cancer caused by the acquisition of gene mutations that bestow deregulated proliferation, impaired differentiation. There is continuing interest to recognize the signaling pathways and genes that play a crucial function in carcinogenesis and the development of resistance to antitumor drugs. The histone deacetylases (HDACs) has been found to interact with many partners through complex molecular mechanism leading to the regulation of gene expression, they have obtained the interest of a large number of researchers. Several HDAC inhibitors (HDACis) have been confirmed to proficiently protect against the growth of tumor cells in vitro as well as in vivo. Thus it is expected that some of the HDACi could be potential effective anti-leukemic drugs. In this book, we have summarized the current status of different classes of HDACs, epigenesis, apoptosis and role of HDAC inhibitors in therapeutics for the treatment of different types of leukemia.
Author: Tso-Pang Yao
Publisher: Springer Science & Business Media
ISBN: 3642216315
Category : Medical
Languages : en
Pages : 269
Get Book Here
Book Description
The book highlights work from many different labs that taught us abnormal HDACs potentially contribute to the development or progression of many human diseases including immune dysfunctions, heart disease, cancer, memory impairment, aging, and metabolic disorders.
